Darolutamide and ADT before prostate surgery
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a combination of darolutamide (a hormone-blocking pill) and standard hormone therapy (ADT) given before prostate surgery. It is for men with high-risk prostate cancer that has not spread to distant parts of the body, to see if the treatment can improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Men aged 18 and older
- Prostate cancer confirmed by biopsy, with no spread to distant organs
- High-risk features: Gleason score 8 or higher, PSA over 20, or tumor felt to be stage T3 or higher
- A candidate for surgery to remove the prostate, with or without removing nearby lymph nodes
- Good overall health (able to care for yourself) and normal kidney, liver, and blood counts
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests darolutamide (a hormone blocker pill) with or without standard hormone therapy given before surgery for high-risk prostate cancer. The goal is to see if this combination can shrink the cancer and improve outcomes before the prostate is removed.
This trial tests a combination of darolutamide (a pill that blocks male hormones) and standard hormone therapy (ADT) for men with high-risk prostate cancer that has not spread beyond the pelvis, after their prostate has been removed. The goal is to see if this treatment can help prevent the cancer from coming back.
This study looks at combining a drug called darolutamide with standard hormone therapy for men whose prostate cancer has spread to the lymph nodes after surgery. The goal is to see if this combination helps prevent the cancer from coming back.
This trial tests giving a new hormone-blocking drug (darolutamide) plus standard hormone therapy before surgery for men with high-risk prostate cancer that has not spread. The goal is to see if this approach improves outcomes.
This study tests a combination of three treatments (darolutamide, docetaxel, and hormone therapy) given before surgery for men with locally advanced prostate cancer that hasn't spread. The goal is to see if this approach is safe and effective in shrinking the cancer before surgery.
This trial tests a combination of a hormone therapy pill (darolutamide) and a high-dose, precise form of radiation for men with localized prostate cancer that has high-risk features of coming back. The goal is to see if this approach is more effective than standard treatment.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.